Table 1.
Patient demographics and clinical characteristics. (n: number of participants; IQR: interquartile range; none of the comparisons were significantly different)
| Demographics and Clinical Characteristics | Placebo (n = 9) | Drug (n = 11) | |
|---|---|---|---|
| Age median (IQR) | Years | 55 (48–66) | 57 (45–61.5) |
| Sex n(%) | Male | 4 (44.4%) | 9 (81.8%) |
| Female | 5 (55.6%) | 2 (18.2%) | |
| Oxygen at randomization n(%) | Room air | 0 | 0 |
| Nasal cannula | 8 (88.9%) | 7 (63.6%) | |
| High flow nasal cannula | 1 (11.1%) | 3 (27.3%) | |
| Noninvasive ventilation/BiPAP | 0 | 1 (9.1%) | |
| Days median(IQR) | Begin symptoms to admission | 7 (7–8) | 8 (2–9.5) |
| Admission to consent | 3 (2–4) | 3 (2–5) | |
| Length of hospital stay | 7 (6–8) | 11 (6–21) | |
| Days of drug-/ placebo-administered | 5 (4–6) | 4 (2.5–8.5) | |